A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer

BACKGROUND: The prevalence and cancer-specific death rate of lung cancer (LC) have risen in recent decades. A universally applicable prognostic signature for both adenocarcinoma LC (LUAD) and squamous cell carcinoma LC (LUSC) is still lacking. METHODS: A total of 453 patients from The Cancer Genome...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hai, Xu, Xianquan, Ge, Tengfei, Hua, Congshu, Zhu, Xiaodong, Wang, Qikui, Yu, Zaicheng, Zhang, Renquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455901/
https://www.ncbi.nlm.nih.gov/pubmed/34557029
http://dx.doi.org/10.2147/IJGM.S327641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455901/
https://www.ncbi.nlm.nih.gov/pubmed/34557029
http://dx.doi.org/10.2147/IJGM.S327641

Ejemplares similares